



DECEMBER 12<sup>th</sup>, 2022  
1:00 pm CET

## CLINICAL EXPERIENCE WITH BIOBETTERS IN IBD

Biosimilars are increasingly used to treat patients with IMIDs. Biobetters have changed the way oncology patients are treated. Biobetters may be associated with improvements in clinical outcomes and drug pharmacology. The first anti-TNF biobetter was recently approved for IBD.

What is a biobetter?

What is the current level of evidence in IBD?

What are the indications of biobetters in IBD?

These questions will be answered during this interactive webinar.

*Chairs: Silvio Danese, Italy*

*Laurent Peyrin-Biroulet, France*

### FACULTY

**Silvio Danese**

Professor of Gastroenterology,  
Head of Gastroenterology and Endoscopy  
San Raffaele Hospital, Milan, Italy

**Laurent Peyrin-Biroulet**

Full Professor of Medicine IBD Unit  
Department of Gastroenterology Nancy  
University Hospital, France

**Shomron Ben-Horin**

Chair, Israel IBD Society  
Chief, Gastroenterology Department  
Sheba Medical Center, Tel-Aviv University, Israel

**Gionaata Fiorino**

IBD Center  
Gastroenterology and Endoscopy  
San Raffaele Hospital, Milan, Italy

**Subrata Ghosh**

Professor, Chair, Head of Department  
of Medicine College of Medicine & Health  
and APC Microbiome Ireland University College  
Cork - Adjunct professor,  
Universities of Calgary and Birmingham, Ireland

**Intro 5'**

Silvio Danese, *Italy*  
Laurent Peyrin-Biroulet, *France*

**Real-world evidence  
for biobetters in IBD 15'**

Shomron Ben-Horin, *Israel*

**When to initiate? Clinical cases 15'**

Gionata Fiorino, *Italy*

**When to switch? Clinical cases 15'**

Subrata Ghosh, *Ireland*

**Q&A 10'**

[CLICK HERE  
TO REGISTER](#)

Sponsored by



ORGANIZATION OFFICE  
Materia Prima srl  
segreteria@materia1a.it | materia1a.it  
ibdscope@ibdscope.com